Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"
Gilead Sciences has partnered with the White House on the Biden Cancer Moonshot initiative to enhance cancer prevention and early detection among U.S. workers. This initiative aims to improve cancer screening rates through personalized outreach, contributing to a broader effort to combat cancer. Gilead, a biopharmaceutical company known for developing innovative medicines, operates in over 35 countries and is headquartered in Foster City, California. This partnership aligns with Gilead's mission to transform and simplify care for those with life-threatening illnesses by increasing access to vital health screenings.
- None.
- None.
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Gilead Sciences:
In an effort to advance access to cancer prevention and early detection among U.S. workers, the Biden Cancer Moonshot recently announced a series of actions that organizations are taking to improve access and use of cancer screenings. We're proud to be included on the list for our commitment to help increase screening rates among employees through personalized outreach.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Originally published by Gilead Sciences
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com
SOURCE: Gilead Sciences
View the original press release on accesswire.com